CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES

A method of treating a neurodegenerative disorder in a subject, comprising administering an effective amount of a casein kinase 1 delta (ck1δ) inhibitor compound of formula (IC), or a pharmaceutically acceptable salt or solvate thereof:

• wherein
• “Het C” represents pyridinyl, pyrimidinyl or quinazolinyl;
• Xc and Yc independently represent a bond or NH;
• R1c and R2c independently represent phenyl, benzodioxinyl, pyridinyl, pyrazol-4-yl, thiophenyl or benzoxazolyl, wherein R1c and R2c may be substituted by one or more R4c groups;
• R4c represents selected from hydroxyl, methoxy or —CONH2;
• p represents an integer from 0 to 2;
• R3c represents halogen, halo C1-6 alkyl, C1-6 alkyl, hydroxyl, C1-6 alkoxy, —S—C1-6 alkyl, —CH2—S—C1-6 S—C1-6 alkyl, —S—C2-6 alkynyl, amino, cyano, NO2, ═O, ═S, —SO2—C1-6 alkyl, —CONH2, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —NH—C1-6 alkyl, —NH—CO—C1-6 alkyl, —NH—CO—CH═CH—CH2—N(Me)2, C1-6 alkyl, —CO—NH—C1-6 alkyl, —CO—NH—CH(Me)—COOH, —S—CH2—CO—N(Et)2, —NH—(CH2)2—OH, —NH—(CH2)3—OH, —NH—CH(Et)—CH2—OH, —CO—NH—(CH2)3—OH, —CH(CH2OH)2 or —S—CH2—CO—NH—CO—NH—C1-6 alkyl, aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein said aryl, heterocyclyl or heteroaryl groups of R3c may be optionally substituted by one or more R4c groups and wherein said C1-6 alkyl groups of R3c may be optionally substituted by one or more hydroxyl groups;
• with the proviso that the compound is other than compound number 867.